News

Acceleron Launches PULSAR Phase 2 Trial Testing Potential PAH Therapy Sotatercept

Acceleron Pharma, a biopharmaceutical company focused on rare diseases, has announced the start of the PULSAR Phase 2 clinical trial assessing the safety and effectiveness of sotatercept (ACE-011) in adults with pulmonary arterial hypertension (PAH). Sotatercept works by trapping members of the transforming growth factor-beta (TGF-beta) family, particularly those directly…